Annals of Clinical and Translational Neurology (Sep 2022)

Seroprevalence of anti‐myelin oligodendrocyte glycoprotein antibodies in adults with myelitis

  • Ki Hoon Kim,
  • Su‐Hyun Kim,
  • Jae‐Won Hyun,
  • Yeseul Kim,
  • Hyewon Park,
  • Ho Jin Kim

DOI
https://doi.org/10.1002/acn3.51642
Journal volume & issue
Vol. 9, no. 9
pp. 1481 – 1486

Abstract

Read online

Abstract Although myelitis is the second most common presentation in adults with myelin oligodendrocyte glycoprotein (MOG) antibody‐associated disease (MOGAD), studies on MOG‐IgG seroprevalence in patients with myelitis episodes are sparse. Herein, we investigated MOG‐IgG seroprevalence in Korean adults who exhibited myelitis since 2017. Among 151 adults with acute myelitis, 11 (7.3%) tested positive for MOG‐IgG by the initial screening and 10 (6.6%) patients were finally diagnosed with MOGAD during the study period. This study is the first to provide data on MOG‐IgG seroprevalence in adults with myelitis and supports the clinical utility and importance of MOG‐IgG testing in myelitis episodes.